Literature DB >> 1900079

Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.

R J Barth1, J J Mulé, P J Spiess, S A Rosenberg.   

Abstract

We have investigated the mechanisms whereby adoptively transferred murine CD8+ lymphocytes mediate tumor regressions. Noncytolytic, CD8+ tumor-infiltrating lymphocytes (TIL) eradicated established lung tumors in irradiated mice. Many cytolytic and noncytolytic CD8+ TIL cultures specifically secreted interferon gamma (IFN-gamma) and tumor necrosis factor when stimulated with tumor cells in vitro. The effectiveness of TIL when adoptively transferred to mice bearing micrometastases correlated better with their ability to specifically secrete lymphokines than with their cytotoxicity in vitro. In 14 of 15 tests, therapeutically effective TIL specifically secreted IFN-gamma in vitro, whereas only 1 of 11 ineffective TIL specifically secreted IFN-gamma. In contrast, only 8 of 15 therapeutically effective TIL were cytolytic. Antibodies to TNF inhibited the effectiveness of two adoptively transferred TIL cultures. In five experiments, antibodies to IFN-gamma abrogated the ability of four different CD8+ TIL cultures to mediate tumor regressions, indicating that secretion of IFN-gamma is an essential part of the mechanism of action of TIL.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900079      PMCID: PMC2118834          DOI: 10.1084/jem.173.3.647

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  42 in total

1.  The role of IFN-gamma in delayed-type hypersensitivity mediated by Th1 clones.

Authors:  T A Fong; T R Mosmann
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

2.  IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells.

Authors:  E Maraskovsky; W F Chen; K Shortman
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

3.  Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity.

Authors:  M Giovarelli; A Santoni; C Jemma; T Musso; A M Giuffrida; G Cavallo; S Landolfo; G Forni
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

4.  In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.

Authors:  B A Fox; P J Spiess; A Kasid; R Puri; J J Mulé; J S Weber; S A Rosenberg
Journal:  J Biol Response Mod       Date:  1990-10

5.  Demonstration in vitro of cytotoxic T cells with apparent specificity toward tumor-specific transplantation antigens on chemically induced tumors.

Authors:  P H Chauvenet; C P McArthur; R T Smith
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

6.  Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse gamma-interferon complementary DNA.

Authors:  K Nishihara; S Miyatake; T Sakata; J Yamashita; H Kikuchi; Y Kawade; Y Zu; Y Namba; M Hanaoka; Y Watanabe
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

7.  Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.

Authors:  J S Weber; S A Rosenberg
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

8.  Lymphocyte recruitment in delayed-type hypersensitivity. The role of IFN-gamma.

Authors:  T B Issekutz; J M Stoltz; P vd Meide
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

9.  Interferon-gamma: the major mediator of resistance against Toxoplasma gondii.

Authors:  Y Suzuki; M A Orellana; R D Schreiber; J S Remington
Journal:  Science       Date:  1988-04-22       Impact factor: 47.728

10.  Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.

Authors:  D L Fraker; H N Langstein; J A Norton
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  93 in total

1.  A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.

Authors:  Yefei Rong; Xia Qin; Dayong Jin; Wenhui Lou; Lili Wu; Dansong Wang; Wenchuan Wu; Xiaolin Ni; Zhengfa Mao; Tiantao Kuang; Ying Qin Zang; Xinyu Qin
Journal:  Clin Exp Med       Date:  2011-09-20       Impact factor: 3.984

2.  Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.

Authors:  F P Holladay; T Heitz-Turner; W L Bayer; G W Wood
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 3.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

Review 4.  Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

Authors:  N P Restifo; Y Kawakami; F Marincola; P Shamamian; A Taggarse; F Esquivel; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-10

5.  B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.

Authors:  Ming-Ru Wu; Tong Zhang; Albert T Gacerez; Tiffany A Coupet; Leslie R DeMars; Charles L Sentman
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

Review 6.  Intravital imaging of CD8+ T cell function in cancer.

Authors:  Thorsten R Mempel; Christian A Bauer
Journal:  Clin Exp Metastasis       Date:  2008-07-30       Impact factor: 5.150

7.  Role of endogenous interferon gamma in murine tumor growth and tumor necrosis factor alpha antitumor efficacy.

Authors:  G M Doherty; H R Alexander; M J Merino; D J Venzon; J A Norton
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

8.  In situ cytokine production by breast cancer tumor-infiltrating lymphocytes.

Authors:  B J Camp; S T Dyhrman; V A Memoli; L A Mott; R J Barth
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

9.  Intrathecal treatment of C6 glioma leptomeningeal metastasis in Wistar rats with interleukin-2.

Authors:  U Herrlinger; R Buchholz; P Jachimczak; M Schabet
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

10.  Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.

Authors:  W J Murphy; T C Back; K C Conlon; K L Komschlies; J R Ortaldo; T J Sayers; R H Wiltrout; D L Longo
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.